HolderBook

Asymmetry Capital Management, L.P.

Reported holdings as of Q4 2021, from 13 quarterly filings.

This filer last reported in Q4 2021; the most recent quarter on file across all filers is Q2 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1657134
Reported value
$188.4M
Positions
24
Top 10 weight
64.3%
Filed
2022-01-19
Days after quarter end
19

Holdings

SecurityTickerValue SharesWeightWeight change Held Change
BIOMARIN PHARMACEUTICAL INCBMRN$15.7M177,7418.34%-newNEW
HORIZON THERAPEUTICS PUB LHZNP$14.8M137,6107.87%+6.23pp2q+451.6%+$12.1M
UNITEDHEALTH GROUP INCUNH$13.5M26,8447.16%-newNEW
ABBVIE INCABBV$12.8M94,4486.79%-newNEW
IQVIA HLDGS INCIQV$12.5M44,3146.64%-newNEW
CENTENE CORP DELCNC$12.2M148,2546.48%-newNEW
BELLUS HEALTH INC NEWBLU$10.3M1,280,7575.47%+1.51pp2q+19.4%+$1.7M
CYTOKINETICS INCCYTK$10.3M225,0325.44%+0.15pp2q-8.6%-$971.0K
JOHNSON & JOHNSONJNJ$9.5M55,7555.06%-newNEW
NATERA INCNTRA$9.5M101,6745.04%-newNEW
AMICUS THERAPEUTICS INCFOLD$8.3M716,7094.39%+0.64pp3q+9.6%+$724.6K
ARGENX SEARGX$7.3M20,8813.88%-newNEW
KURA ONCOLOGY INCKURA$7.0M502,2753.73%+1.55pp2q+158.5%+$4.3M
APELLIS PHARMACEUTICALS INCAPLS$6.6M139,4453.50%-newNEW
MIRATI THERAPEUTICS INCMRTX$6.4M43,8763.42%-1.05pp4q+4.5%+$276.5K
IVERIC BIO INCISEE$6.3M375,9893.34%-0.13pp2q+5.8%+$344.3K
QUANTERIX CORPQTRX$6.1M143,2043.22%-1.62pp2q-11.6%-$794.1K
ITEOS THERAPEUTICS INCITOS$4.9M104,7552.59%+1.66pp6q+82.9%+$2.2M
DICE THERAPEUTICS INCDICE$4.7M185,2012.49%-2.93pp2q-32.7%-$2.3M
AVADEL PHARMACEUTICALS PLCAVDLXXXX$3.0M369,1341.58%-1.21pp7q-22.2%-$850.4K
ACLARIS THERAPEUTICS INCACRS$2.9M198,4931.53%-1.08pp3q-17.9%-$628.2K
PMV PHARMACEUTICALS INCPMVP$2.3M97,6801.20%-0.61pp6q-3.2%-$74.0K
REGULUS THERAPEUTICS INCRGLS$860.0K2,731,0440.46%-0.13pp4q+94.9%+$418.7K
BCLS ACQUISITION CORPBLSA$699.0K71,3720.37%-0.07pp5q-2.6%-$18.9K

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 45.8%Insurance 13.6%Healthcare Services 5.0%Not classified 35.5%
 
SectorValueShare
Biotech & Pharma$86.3M45.8%
Insurance$25.7M13.6%
Healthcare Services$9.5M5.0%
Not classified$66.8M35.5%

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q4 2021$188.4M249871464.3%19
Q3 2021$166.3M2915681657.5%35
Q2 2021$145.5M30114151061.6%28
Q1 2021$193.3M29133131757.0%41
Q4 2020$219.3M33141531556.8%42
Q3 2020$155.6M3418791652.9%43
Q2 2020$130.5M3214991160.5%37
Q1 2020$91.4M2991731362.0%43
Q4 2019$55.8M3322471149.7%43
Q3 2019$46.7M2282121669.4%43
Q2 2019$184.7M3012180767.4%38
Q1 2019$59.8M2510123872.4%38
Q4 2018$36.2M23000074.5%43

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.